Clinical Conversations: The Data for JAK Inhibitors in AD

Clinical Conversations The Data for JAK Inhibitors in AD thumbnail

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Tolerability of JAK Inhibitors Used in Dermatology
Tolerability of JAK Inhibitors Used in Dermatology
JAK Inhibitors in Practice
Tolerability of JAK Inhibitors Used in Dermatology
- Matthew J. Zirwas, MD
- Adelaide Hebert, MD
Clinical Conversations: Risks vs Benefits of JAK Inhibitors
Clinical Conversations: Risks vs Benefits of JAK Inhibitors
JAK Inhibitors in Practice
Clinical Conversations: Risks vs Benefits of JAK Inhibitors
- Matthew J. Zirwas, MD
- Adelaide Hebert, MD
Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
JAK Inhibitors in Practice
Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
- Matthew J. Zirwas, MD
- Adelaide Hebert, MD
Clinical Conversations: MOA of JAK Inhibitors in Dermatology
Clinical Conversations: MOA of JAK Inhibitors in Dermatology
JAK Inhibitors in Practice
Clinical Conversations: MOA of JAK Inhibitors in Dermatology
- Brad Glick, DO, MPH
- Raj Chovatiya, MD, PhD